LAUSR

Dear Sir, Omalizumab is a recombinant humanized anti-IgE monoclonal antibody that binds the IgE molecule in the region assigned to the target cell receptor. Its main action lies in the reduction of plasma-free IgE levels and an indirect decrease in the number of high-affinity IgE receptors of basophils and mast cells (Metz et al., 2017). Chronic spontaneous urticaria (CSU) represents approximately 70% of all chronic urticarias. In 2009, the EAACI/GA(2)LEN/EDF/ WAO international guidelines were published with the idea of unifying the definition, classification, diagnosis, and treatment of urticaria according to scientific evidence in literature, considering the experience in Europe and around the world (Zuberbier et al., 2009). In 2013, the document was revised and updated and today comprises the agreed-upon European guidelines for the management of chronic spontaneous urticaria (Zuberbier et al., 2014). The main goal of this study is to describe the usage patterns and therapeutic response of UCS patients to omalizumab in real-world clinical practice at five dermatology departments and one allergology